Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02577952 · ClinicalTrials.gov registry record
Lipodystrophy Connect Patient Registry
A clinical trial of Lipodystrophy, sponsored by PatientCrossroads.
- Completed
- Registry status
- 257
- Enrollment target
- 1
- Study location
NCT02577952: Completed study of Lipodystrophy, sponsored by PatientCrossroads.
NCT02577952 is a study of Lipodystrophy that has completed, run by PatientCrossroads. The registered enrollment target is 257 participants, above the 110-participant average among 11 other Lipodystrophy trials with a reported enrollment target (134% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02577952, a study of Lipodystrophy, has completed, sponsored by PatientCrossroads.
- COMPLETED
- Registry status
- 257 participants
- Enrollment target
- 1
- Study location
Study Summary
Lipodystrophy Connect is an online survey tool designed to collect demographic data and health information from individuals with Lipodystrophy.
Primary Outcome
Assessed from multiple questions regarding the natural history of patients with congenital or acquired lipodystrophy, with an emphasis on co-morbidities, history of medical evaluation or admission, and use of medications/alternative therapies.
Conditions Studied
Study Locations (1)
California
- PatientCrossroads - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 257 participants |
| Start Date | 2014-01 |
| Est. Completion | 2018-11-08 |
What the finished NCT02577952 record still lists
NCT02577952 is an observational study that tracks outcomes without assigning an intervention. The registered 257 participants enrollment target is mid-sized for trials with a published cap, above the 110-participant average among 11 other Lipodystrophy trials with a reported enrollment target (134% higher).
The record links to 1 condition, with Lipodystrophy appearing as the primary indexed condition, and to 0 interventions.
NCT02577952 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02577952 about?
NCT02577952 is a clinical study titled "Lipodystrophy Connect Patient Registry". Lipodystrophy Connect is an online survey tool designed to collect demographic data and health information from individuals with Lipodystrophy.
What is the current status of trial NCT02577952?
This trial is currently completed. The enrollment target is 257 participants. The study started on 2014-01. Estimated completion is 2018-11-08.
What conditions does trial NCT02577952 study?
This clinical trial studies the following conditions: Lipodystrophy.
Who is sponsoring clinical trial NCT02577952?
This trial is sponsored by PatientCrossroads, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02577952 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lipodystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02577952's enrollment target sits among peer trials
257 3rd of 11 higher than 9 of 11 other Lipodystrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lipodystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy
RECRUITING
-
Feasibility of Adipose Tissue Triglyceride (TG) Labelling in Familial Partial Lipodystrophy (FPLD)
RECRUITING
-
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
ACTIVE NOT RECRUITING · Phase 2
-
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension
COMPLETED · Phase 2
-
Exercise and Pioglitazone for HIV-Metabolic Syndromes
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03618550 · 257 participants · Phase 2
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
- NCT04674267 · 257 participants · NA
Resilience and Equity in Aging, Cancer, and Health (REACH)
- NCT06099288 · 257 participants · NA
Strong Families Start at Home/Familias Fuertes Comienzan en Casa
- NCT06207084 · 257 participants · NA
The Fit With Us Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia